Sarepta Therapeutics, Inc. (SRPT)

The long-term investment case is severely compromised by a collapse in business quality. Revenue has plummeted by 34% year-over-year, and gross margins are deeply negative at -17%, signaling a fundamental breakdown in the company's ability to generate profit from its sales. While the balance sheet remains technically liquid with a current ratio above 4, the operational reality is dire: the company is burning cash, losing market share, and failing to execute on its core product lifecycle. The stock has lost over 85% of its value in the trailing twelve months, a reflection of the market pricing out the deteriorating fundamentals. The recent appointment of a new CEO offers hope, but without immediate, tangible evidence of a strategic pivot or revenue stabilization, the business appears to be in a structural decline. The short-term outlook is similarly bleak; despite a recent bounce off the lows, the stock is trading below its 200-day moving average, and the statistical forecast models see no upward momentum. The massive options activity at extreme strikes confirms that investors are treating this as a high-risk gamble on a miracle cure rather than a stable investment. Until the revenue bleed stops and margins turn positive, this remains a speculative vehicle for distressed investors, not a viable holding for capital preservation or growth.